---
title: "Descartes-08 in Generalized myasthenia gravis: Pharmacodynamics"
description: "Formulary evidence on Descartes-08 in Generalized myasthenia gravis: Pharmacodynamics. Topics: Preclinical activity: CAR expression peaks on day 1 and BCMA-positive cells are killed, Plasmablast BCMA and pDC activation markers after treatment compared with placebo: phase 2b, Autoantibody repertoire and anti-AChR antibody titers: phase 2b, Anti-AChR antibody reductions in the phase 2a portion, and 3 further topics. 7 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description/pharmacodynamics"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Descartes-08 in Generalized myasthenia gravis: Pharmacodynamics

<a id="heading-2.1.2.6.2"></a>

## 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

### Preclinical activity: CAR expression peaks on day 1 and BCMA-positive cells are killed

> “To confirm function, the Descartes-08 RNA payload was electroporated into CD8+ T cells.”
> “CAR RNA was rapidly detected and then gradually waned to baseline (Fig. 1e), consistent with expression that peaked on day 1 (Fig. 1f).”
> “Descartes-08 also efficiently depleted autologous PCs from healthy individuals or patients with MG (Fig. 1h,i and Supplementary Fig. 2).”

Source: [Fedak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004674/)

> “The magnitude of cytolysis correlates with anti-BCMA CAR expression duration, indicating a temporal limit in activity.”

Source: [Lin et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7785573/)

<a id="topic-2.1.2.6.2-2"></a>

### Plasmablast BCMA and pDC activation markers after treatment compared with placebo: phase 2b

> “Intriguingly, analysis of plasmablasts after Descartes-08 treatment revealed significant reductions in BCMA expression on plasmablasts at month 3 (n = 6) (P = 0.035) compared to placebo.”
> “Similarly, CD86 was significantly reduced on pDCs at month 1 (n = 11) (P < 0.001) relative to placebo and also trended downward at month 3 (Fig. 3e,f).”
> “Interestingly, at month 12, the decrease in CD86 levels persisted among the Descartes-08 cohort (Extended Data Fig. 2), although fewer samples were available at month 12 (n = 7).”
> “Despite the changes in activation state, the frequency of plasmablasts and circulating pDCs remained unchanged (Fig. 3g,h), consistent with the normal levels observed at screen (Fig. 3a,b).”

Source: [Fedak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004674/)

<a id="topic-2.1.2.6.2-3"></a>

### Autoantibody repertoire and anti-AChR antibody titers: phase 2b

> “By contrast, Descartes-08 was associated with a greater change in the autoreactome (r value median = 0.72) compared to placebo (r value median = 0.89) at month 3 compared to day 1; this change persisted through month 6 (r value median = 0.74) (Fig. 3j).”
> “Furthermore, despite the dramatic changes in autoreactome, we did not observe a significant change in the anti-AChR antibody titer (Fig. 3m).”

Source: [Fedak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004674/)

<a id="topic-2.1.2.6.2-4"></a>

### Anti-AChR antibody reductions in the phase 2a portion

> “All three participants with detectable anti-acetylcholine receptor antibody levels before treatment had an average 42% reduction in antibody levels by Month 6.”
> “These reductions deepened to 68% by Month 9 and persisted at Month 12.”

Source: [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm)

<a id="topic-2.1.2.6.2-5"></a>

### Immune cell populations, immunoglobulins, and vaccine titers at month 3 and month 12: phase 2b

> “In line with our hypothesis, no significant changes were observed between placebo and Descartes-08 when assessing broad immune populations, including the change in frequency of B cells, T cells, natural killer cells and monocytes (Fig. 4a–e and Supplementary Fig. 8).”
> “Likewise, total immunoglobulins (Fig. 4f–h and Extended Data Table 3) and common vaccine titers (Fig. 4i–m and Extended Data Table 4) were preserved at month 3 and month 12.”

Source: [Fedak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004674/)

<a id="topic-2.1.2.6.2-6"></a>

### Disease-associated cytokines after infusion: phase 2b

> “Descartes-08 infusion was not associated with indicators of CAR-T cell therapy-induced inflammation.”
> “In particular, IL-6, IL-24, CCL19 and artemin (ARTN), all of which are involved in autoimmunity, decreased at month 3 as well as at month 1 and month 12 for some analytes.”
> “Importantly, IL-6 is a key indicator of MG severity, and this cytokine was significantly reduced at month 3 in patients receiving Descartes-08 (P = 0.019).”

Source: [Fedak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004674/)

<a id="topic-2.1.2.6.2-7"></a>

### T cell receptor repertoire after treatment

> “TCR sequencing revealed that Descartes-08 increases clonal expansion and contraction compared to placebo (Fig. 6a,b).”
> “Together, these data indicate that Descartes-08 alters the TCR repertoire without significantly changing the broader phenotypic composition of the T cell compartment.”

Source: [Fedak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004674/)

## Related pages
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis.md)
- [Descartes-08 in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary.md)
- [Descartes-08 in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Descartes-08 in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence.md)
- [Descartes-08 in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics.md)
- [Descartes-08 in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references.md)
